The marked upregulation of CCL2 observed in this study aligns with its established role in amplifying inflammatory responses in IBD, suggesting it is a prospective focus for treatment strategies aimed at reducing ICI and curbing inflammation. The gene discussed is CCL2; the disease is inflammatory bowel disease.